SEARCH

SEARCH BY CITATION

References

  • 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 3749.
  • 2
    EMEA, Committee for Proprietary Medicinal Products. Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. London: European Agency for the Evaluation of Medicinal Products, 2004.
  • 3
    FDA. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: . U.S. Department of Health and Human Services, Food and Drug Administration, 2009: 139.
  • 4
    Patrick DL, Burke LB, Powers JH et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10 (Suppl. 2): S12537.
  • 5
    Barry MJ, Fowler Jr FJ, O’Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 154957; discussion 64.
  • 6
    Barry MJ, Girman CJ, O’Leary MP et al. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group. J Urol 1995; 153: 99103.
  • 7
    Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 17704.
  • 8
    Donovan JL, Abrams P, Peters TJ et al. The ICS-’BPH’ Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 1996; 77: 55462.
  • 9
    Donovan JL, Brookes ST, de la Rosette JJ et al. The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-’BPH’ study. BJU Int 1999; 83: 2438.
  • 10
    Jackson S, Donovan J, Brookes S et al. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol 1996; 77: 80512.
  • 11
    Barry MJ, Williford WO, Fowler FJ Jr et al. Filling and voiding symptoms in the American Urological Association symptom index: the value of their distinction in a Veterans Affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia. J Urol 2000; 164: 155964.
  • 12
    Hald T, Nordling J, Andersen JT et al. A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1991; 138: 5962.
  • 13
    Hansen BJ, Flyger H, Brasso K et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995; 76: 4518.
  • 14
    Glover L, Gannon K, McLoughlin J, Emberton M. Men’s experiences of having lower urinary tract symptoms: factors relating to bother. BJU Int. 2004; 94: 5637.
  • 15
    Gannon K, Glover L, O’Neill M, Emberton M. Men and chronic illness: a qualitative study of LUTS. J Health Psychol. 2004; 9: 41120.
  • 16
    Wareing M. Lower urinary tract symptoms: a hermeneutic phenomenological study into men’s lived experience. J Clin Nurs 2005; 14: 23946.
  • 17
    Kinchen KS, Burgio K, Diokno AC et al. Factors associated with women’s decisions to seek treatment for urinary incontinence. J Womens Health (Larchmt) 2003; 12: 68798.
  • 18
    Hagglund D, Ahlstrom G. The meaning of women’s experience of living with long-term urinary incontinence is powerlessness. J Clin Nurs 2007; 16: 194654.
  • 19
    DuBeau CE, Levy B, Mangione CM, Resnick NM. The impact of urge urinary incontinence on quality of life: importance of patients’ perspective and explanatory style. J Am Geriatr Soc 1998; 46: 68392.